October 29th 2024
The indication for Jylamvo now includes pediatric patients with acute lymphoblastic leukemia.
October 28th 2024
Onvansertib May Be a New Frontline Option for Patients With Venetoclax-Resistant AML
December 5th 2019Onvansertib inhibits tumor growth in patients with acute myeloid leukemia who are resistant to venetoclax, according to the in-vitro and in-vivo data from a phase II trial announced in a press release issued by Trovagene, Inc.
Read More
A Look Back at FDA News from November 2019
December 2nd 2019In November 2019, the FDA approved a number of treatments, including acalabrutinib for the treatment of chronic lymphocytic leukemia and small lymphocytic leukemia, as well as zanubrutinib for the treatment of mantle cell lymphoma. A biosimilar for pegfilgrastim was also approved under indications.
Read More
Age Impacts Treatment Options for Patients With CLL
November 21st 2019Kanti R. Rai, MD, professor of medicine, Northwell Health and Zucker School of Medicine at Hofstra University, explains the importance of attention to age when treating patients with chronic lymphocytic leukemia, which is a typically elderly patient population.
Watch
Optimizing Use of Prognostic Markers for the Treatment of CLL
November 20th 2019In an interview with Targeted Oncology at the 2019 Chemotherapy Foundation Symposium, Richard R. Furman, MD, reviewed his presentation on prognostic markers and their importance in the treatment of patients with chronic lymphocytic leukemia.
Read More
Resistance Mutations Pose Complex Challenges for Pathologists
November 13th 2019The emergence of resistance mutations in patients with cancer who receive targeted therapies is an expected development that will require new diagnostic methods of identifying the mechanisms through which these alterations occur, according to Fei Dong, MD, during the 2019 Association for Molecular Pathology Annual Meeting.<br />
Read More
Ibrutinib/Rituximab Seeking Approval As Frontline Treatment for CLL
November 13th 2019A supplemental New Drug Application for the combination of ibrutinib and rituximab has been submitted to the FDA for the first-line treatment of patients aged 70 years or younger with chronic lymphocytic leukemia or small lymphocytic lymphoma, according to a press release from ibrutinib developer, AbbVie.
Read More
The Importance of Molecular Monitoring in the Treatment of AML
November 13th 2019In an interview with Targeted Oncology, Eytan M. Stein, MD, reviews the current treatment landscape of acute myeloid leukemia, underscores the importance of molecular monitoring, and highlights where the field is headed.
Read More
Novel Combinations Represent Next Phase for Adult ALL
November 7th 2019A number of promising biologic therapies are beginning to transform the treatment of adult patients with acute lymphoblastic leukemia, with the greatest potential seen with blinatumomab and inotuzumab ozogamicin in combination with chemotherapy, according to a presentation by Hagop M. Kantarjian, MD, at the 37th Annual CFS.<br />
Read More
Results from Phase III Study of Gilteritinib Versus Chemotherapy Published in NEJM
November 4th 2019Detailed results of the phase III ADMIRAL trial, which evaluated the use of gilteritinib in adult patients with FLT3 mutation–positive relapsed or refractory acute myeloid leukemia, have been published in the New England Journal of Medicine and reaffirm the improved overall survival rate seen with gilteritinib compared with chemotherapy in these patients, according to a press release from Astellas Pharma Inc.
Read More
A Look Back at FDA News from October 2019
November 1st 2019In October 2019, the FDA approved a new treatment option for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer, as well as a new dosing regimen for patients receiving moderately emetogenic chemotherapy. Additionally, the FDA granted breakthrough therapy designations to 2 therapies, as well as an orphan drug designation, a priority review, and 2 fast track designations.
Read More
SY-1425 Plus Azacitidine Continues to Show Durable Activity in RARA+ AML
October 25th 2019In the phase II biomarker-driven trial combining retinoic acid receptor alpha agonist SY-145 with azacitidine, newly diagnosed adult patients with RARA-positive acute myeloid leukemia who were unfit for intensive chemotherapy continued to show responses to the combination and demonstrate tolerability of the regimen, according to a press release from Syros Pharmaceuticals.
Read More
Long-Term Ublituximab Plus Ibrutinib Results Show PFS Benefit in High-Risk CLL
October 25th 2019Ublituximab in combination with ibrutinib demonstrated a benefit in progression-free survival over ibrutinib monotherapy, as assessed by an independent review committee, in patients with high-risk relapsed or refractory chronic lymphocytic leukemia in the final long-term results of the phase III GENUINE trial.
Read More
Selecting the Appropriate Patients for Targeted Therapies in Acute Myeloid Leukemia
October 23rd 2019John DiPersio, MD, PhD, discusses targeted therapies for myeloid malignancies using DARTs, Bites, and antibody–drug conjugates, a topic he presented during the 2019 Society for Hematologic Oncology Annual Meeting.
Watch
Bemcentinib Granted FDA Fast Track Designation for R/R AML
October 23rd 2019Bemcentinib, a first-in-class AXL inhibitor, has been approved for a fast track designation by the FDA for the treatment of elderly patients with relapsed or refractory acute myeloid leukemia, according to a press release from BerGenBio.<br />
Read More
Frontline Ivosidenib/Azacitidine Combo Shows Early Promising Efficacy in IDH1+ AML
October 19th 2019Ivosidenib in combination with azacitidine demonstrated promising efficacy in addition to being well tolerated in patients with newly diagnosed <em>IDH1</em>-mutant acute myeloid leukemia who were ineligible for intensive chemotherapy.
Read More
AML Relapse Predictive Ability of ctDNA Comparable With Bone Marrow Mutation Persistence
October 15th 2019Among patients with acute myeloid leukemia and myelodysplastic syndrome who completed myeloablative allogeneic hematopoietic stem cell transplantation, the predictive utility of testing circulating tumor DNA was comparable with that of mutation persistence evaluation in matched bone marrow samples, according to a study published recently in Blood.
Read More
Treating ALL With Cellular and Targeted Immunotherapies Reduces the Need for Transplant
October 12th 2019The advent of an era of targeted immunotherapy and CAR T-cell therapies for the treatment of adult patients with acute lymphoblastic leukemia may reduce the need for hematopoietic stem cell transplant in certain cases.<br />
Read More
Analyzing Real-World Data for CAR T-Cell Therapy in Patients With ALL and DLBCL
October 7th 2019Marcelo C. Pasquini, MD, discusses the rationale for analyzing real-world data for the use of tisagenlecleucel, a chimeric antigen receptor T-cell therapy, as a treatment for patients with acute lymphoblastic leukemia and diffuse large B-cell lymphoma. This CD19 CAR T cell was approved 2 years ago for use in both ALL and DLBCL.
Watch
Blinatumomab Trials Stopped After Benefit is Observed in Pediatric ALL
October 2nd 2019Due to treatment benefit observed in pediatric patients with acute lymphoblastic leukemia, 2 clinical trials investigating blinatumomab (Blincyto) versus chemotherapy were stopped early, according to the drug developer Amgen.
Read More
Durable Responses Demonstrated in Phase I/II With U2 Triplet Regimen in CLL
September 28th 2019Umbralisib and ublituximab in combination with pembrolizumab was well tolerated among patients with relapsed/refractory chronic lymphocytic leukemia and Richter’s transformation, according to a phase I/II trial presented at the 18th International Workshop on CLL. Responses were durable in high-risk patients who are BTK-refractory, including 2 complete responses in patients with RT.
Read More
Real-World Tisagenlecleucel Data Match Trial Results in Patients With ALL and DLBCL
September 25th 2019In an interview with <em>Targeted Oncology</em>, Marcelo C. Pasquini, MD, discussed the importance of obtaining real-world data and establishing registries for collecting patient outcomes, and how real-world data compare with data from pivotal trials. He also explained the challenges with accessibility to CAR T-cell therapies.
Read More
Favorable Safety Profile Demonstrated With Umbralisib in Pretreated CLL
September 25th 2019The PI3K-delta inhibitor umbralisib demonstrated a favorable toxicity profile as treatment for patients with chronic lymphocytic leukemia who have become intolerant to a prior kinase inhibitor, of either BTK or PI3K inhibition, according to results from a phase II study presented at the 18th International Workshop on CLL.
Read More
Expert Highlights Frontline Advancements in Treatment Landscape for CML
September 19th 2019In an interview with <em>Targeted Oncology</em>, Neil P. Shah, MD, PhD, discussed the latest advancements in the treatment landscape of chronic myeloid leukemia, including the introduction of tyrosine kinase inhibitors. He also addressed some of the challenges both oncologists and patients face in this space.<br />
Read More
FLT3 Inhibitors Impact Treatment Landscape for Patients With FLT3-Mutated AML
September 18th 2019Gail Roboz, MD, discusses the use of FLT3 inhibitors as treatment of patients with acute myeloid leukemia, which can be a heterogenous and difficult-to-treat disease. There is a lot of optimism for new drugs and targets in AML, but the disease itself remains tough to treat, according to Roboz.
Watch